Cerebrolysin vs Pinealon
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.
Full profilePinealon
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation and Gerontology — the same institution behind Epithalon and Cortexin. It is a short peptide bioregulator targeting the pineal gland and central nervous system. Research suggests it acts as an epigenetic regulator, penetrating cell nuclei to modulate gene expression in neurons, with reported effects on sleep quality, neuroprotection, circadian rhythm regulation, and age-related cognitive decline.
Full profile| Cerebrolysin | Pinealon | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture | EDR, Glu-Asp-Arg, Pineal tripeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access | 100mcg–300mcg mcg, Once daily (evening, given melatonin/sleep effects) |
| Administration | Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common) | Subcutaneous injection, Intranasal, Oral (sublingual for better absorption) |
| Key side effects | Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea | Generally well-tolerated, Drowsiness if dosed during the day, Vivid dreams (common — melatonin pathway activation), Mild headache (uncommon) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); Pinealon — Subcutaneous injection, Intranasal, Oral (sublingual for better absorption).
- Dosing units differ: Cerebrolysin is dosed in mL, Pinealon in mcg — they operate at different scales.
- Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; Pinealon is Once daily (evening, given melatonin/sleep effects).
- Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for Pinealon.
How each works
Cerebrolysin
Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.
Pinealon
Like other peptide bioregulators from the Khavinson group, Pinealon is proposed to work by penetrating the nuclear membrane and interacting directly with histones and promoter regions to regulate transcription. In vitro studies show Pinealon increases synthesis of serotonin and melatonin precursors in pinealocytes and upregulates antioxidant enzyme expression in neuronal cells. Animal studies demonstrate reduced neuronal apoptosis after hypoxic stress and improved performance in cognitive tasks. Clinical observations from Russian gerontology practice suggest benefits for insomnia, age-related cognitive decline, and neurological recovery.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.